Covid 19 Research using Clinical Trials (Home Page)
Tinzaparin or unfractionated heparinWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent Covid-19 or infection with SARS-CoV-2 or therapeutic agent to treat COVID-19. This protocol CORIMUNO19-COAG will evaluate the efficacy and safety of active anticoagulation using heparin: Tinzaparin (INNOHEP®) or unfractionated heparin (Calciparine®, Héparine Sodique Choay®) in COVID-19 patients hospitalized in conventional or intensive care units. It will use a phase 2 randomized open-label multicentre clinical trial, where patients will be randomly allocated to anticoagulation versus Standard of Care.
NCT04344756 COVID19 Pneumonia Drug: Tinzaparin or unfractionated heparin MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: group 1
Measure: Survival without ventilation (VNI or mechanical ventilation) Time: day 14
Description: group 2
Measure: ventilator free survival Time: day 28
Secondary Outcomes
Description: range from 0 (healthy) to 10 (death) values below or equal to 5 correspond to the absence of any oxygen supply beside nasal or facial mask
Measure: World Health Organisation(WHO) progression scale ≤5 Time: day 4
Description: range from 0 (healthy) to 10 (death)
Measure: World Health Organisation(WHO) progression scale Time: day 4, 7 and 14
Measure: overall survival Time: day 14, 28 and 90
Measure: Length of hospital stay Time: day 28
Measure: Length of ICU stay Time: day 28
Measure: time to oxygenation supply independency Time: day 28
Measure: time to ventilator (non invasive or invasive) Time: day 28
Description: according to Acute Kidney Injury (AKIN) classification system
Measure: rate of acute kidney injury Time: day 28
Measure: time to Renal Replacement Therapy (RRT) initiation Time: day 28
Description: confirmed by objective testing
Measure: rate of clinically overt pulmonary embolism or proximal deep vein thrombosis Time: day 14 and day 90
Description: confirmed by objective testing
Measure: Rate of clinically overt arterial thrombosis Time: day 14 and day 90
Measure: Rate of unscheduled central venous catheter replacement for catheter dysfunction Time: day 28
Description: as a thrombus extending from the catheter into the lumen of the deep vein where the catheter is inserted diagnosed with radiologic imaging in case of a clinical suspicion of upper/lower limb DVT or pulmonary embolism or compulsory catheter removal
Measure: Rate of central venous catheter-related deep vein thrombosis (CVC-DVT) Time: day 28
Measure: Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction Time: day 28
Measure: Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not Time: day 28
Measure: Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system Time: day 28
Measure: Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system Time: day 28
Measure: Incidence of adverse events Time: day 28
Related HPO nodes (Using clinical trials)
HP:0002090: Pneumonia
Genes 208
TIMM8A DNAH9 GAS8 DNAH11 TNFRSF11A TBC1D24 SPAG1 MS4A1 GAS2L2 CCDC151 NIPBL BTK LIG4 NFKB2 TCIRG1 IGLL1 RNF168 STAT3 TAF1 RSPH4A CFTR NME8 DNAAF4 LEP CCDC65 NADK2 CD55 COL11A2 NHLRC1 PEPD CFAP300 LTBP3 WAS DNAI1 TBCD IL2RG GFI1 NBN RSPH1 CCDC39 PMM2 ICOS TNFSF12 IFNGR1 CARD11 SFTPC DNAL1 OFD1 ZMYND10 IL21R FMO3 SLC35A1 PLOD1 ORC6 RAG2 CACNA1C GAS8 RYR1 CFAP298 GNPTAB TNFRSF13B KDM6A PANK2 RANBP2 CYBA USB1 UBB DOCK8 ADA DNAAF2 KMT2D SAMD9 MUC5B IL7R DNAAF1 ICOS RAG2 CARD11 PTPRC ALMS1 NOTCH3 NSMCE3 DNAI1 TNFRSF13C GRHL3 EGFR IL2RG DNAAF6 PNP DNAH5 SETBP1 CR2 CD3E ADA MASP2 SFTPA2 ACTA1 RAC1 TTC25 FCGR2A ZAP70 SPEF2 IGHM DNAAF5 NBN CD247 DDR2 CD19 ACADVL KIAA0586 TK2 BLNK ARMC4 SGCG RAG1 CXCR4 NCF1 SRP54 FOXP3 IRF8 CFAP221 RNU4ATAC KCNJ6 LRBA CD3D P4HTM SELENON CCDC114 TNFRSF13B PLG DCLRE1C SLC25A24 DCLRE1C ICOS IL7R FOXJ1 JAK3 IL2RG CASP8 RAG1 OSTM1 CFAP410 CCNO NCF2 UNC119 TNFRSF13C JAK3 RNF125 STK36 POLA1 CD19 CR2 DNAH1 RSPH3 RSPH9 CYBB DRC1 DCLRE1C CCDC103 DNAAF3 LRRC56 PIGN LRRC6 SP110 PRKCD ACP5 CCDC40 SLC35C1 BTK MTHFD1 PGM3 RAG1 TERT CHD7 CFB TGFB1 RNU4ATAC SMARCD2 NKX2-1 OFD1 ZBTB24 BTK DNAI2 WDR19 ZAP70 CD79B CD81 COL11A2 NFIX RAG2 ELANE AFF4 NFKB1 IL2RG TNFRSF13C TNFSF12 CCDC114 ADA GBA DNAJB13 RPGR CSPP1 RMRP EPM2A DNMT3B NFKB2 MCIDAS HYDIN SNP 0
Primary Outcomes
Description: group 1
Measure: Survival without ventilation (VNI or mechanical ventilation) Time: day 14Description: group 2
Measure: ventilator free survival Time: day 28Secondary Outcomes
Description: range from 0 (healthy) to 10 (death) values below or equal to 5 correspond to the absence of any oxygen supply beside nasal or facial mask
Measure: World Health Organisation(WHO) progression scale ≤5 Time: day 4Description: range from 0 (healthy) to 10 (death)
Measure: World Health Organisation(WHO) progression scale Time: day 4, 7 and 14Measure: overall survival Time: day 14, 28 and 90
Measure: Length of hospital stay Time: day 28
Measure: Length of ICU stay Time: day 28
Measure: time to oxygenation supply independency Time: day 28
Measure: time to ventilator (non invasive or invasive) Time: day 28
Description: according to Acute Kidney Injury (AKIN) classification system
Measure: rate of acute kidney injury Time: day 28Measure: time to Renal Replacement Therapy (RRT) initiation Time: day 28
Description: confirmed by objective testing
Measure: rate of clinically overt pulmonary embolism or proximal deep vein thrombosis Time: day 14 and day 90Description: confirmed by objective testing
Measure: Rate of clinically overt arterial thrombosis Time: day 14 and day 90Measure: Rate of unscheduled central venous catheter replacement for catheter dysfunction Time: day 28
Description: as a thrombus extending from the catheter into the lumen of the deep vein where the catheter is inserted diagnosed with radiologic imaging in case of a clinical suspicion of upper/lower limb DVT or pulmonary embolism or compulsory catheter removal
Measure: Rate of central venous catheter-related deep vein thrombosis (CVC-DVT) Time: day 28Measure: Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction Time: day 28
Measure: Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not Time: day 28
Measure: Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system Time: day 28
Measure: Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system Time: day 28
Measure: Incidence of adverse events Time: day 28